Top in hem/onc: Ovarian cancer vaccine, liver cancer treatment
Recent data on gemogenovatucel-T showed the novel vaccine appeared to benefit women with BRCA wild-type and homologous recombination-proficient ovarian cancer.
A report on the double-blind, placebo-controlled trial was the top story in hematology/oncology last week.
Meanwhile, breakthrough treatments for liver cancer offer new hope for the fastest-growing cause of cancer-related death in the country, according to experts. It is estimated that liver and intrahepatic bile duct cancer will become the third most common cause of cancer-related death by 2040.
Read these and more top stories in hematology/oncology below:
Novel vaccine safe, effective in ovarian cancer subset
A novel vaccine appeared to be safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting. Read more.
New approvals for liver cancer mark ‘golden age’ of treatment
Liver cancer has been notoriously difficult to treat. Healio spoke with oncologists on the front lines about the expanding treatment landscape within the field, evolving studies of drug combinations and biomarkers, and the push to answer remaining questions that may drive the next breakthrough. Read more.
Lisinopril may prevent cardiotoxicity of anthracycline, trastuzumab use in breast cancer
A decrease in left ventricular ejection fraction to below normal levels occurred more frequently among women with HER2-positive early-stage breast cancer who received anthracyclines prior to trastuzumab, according to study results. Read more.
FDA lifts hold on trials of gene therapies for sickle cell disease, beta-thalassemia
The FDA lifted the clinical holds on four studies designed to evaluate two gene therapies for hematologic conditions. Read more.
Sotorasib shows activity in non-small cell lung cancer with KRAS mutations
Sotorasib conferred durable clinical benefit among previously treated patients with KRAS p.G12C-mutated non-small cell lung cancer, according to results of the phase 2 CodeBreaK 100 trial presented during the virtual ASCO Annual Meeting. Read more.